Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|February 10, 2023

SCOPE 2023: Biospecimen Presentation Questions & Insights

Hope Meely, chief clinical officer at Slope, discusses the feedback she received following her SCOPE presentation around biospecimen collection.

In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Hope Meely, chief clinical officer at Slope, elaborates on the feedback she received surrounding her conference presentation, "The Hidden Regulatory Risk from Sample Management — What Should You Be Aware of?” This includes the agreement among attendees that the clinical trials industry needs to ensure that biospecimens are managed, especially since they are the driving factors of safety and efficacy data.


Related to this article

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.